GeneralResearch & Publications

Racial disparity in glucagon-like peptide 1 and inflammation markers among severely obese adolescents

By April 1, 2008September 24th, 2020No Comments


Diabetes Care

Pedro A Velásquez-Mieyer 1 ,
Patricia A Cowan,
Sylvia Pérez-Faustinelli,
Ramfis Nieto-Martínez,
Cesar Villegas-Barreto,
Elizabeth A Tolley,
Robert H Lustig,
Bruce S Alpert

Objective: Compared with Caucasians, obese African-American adolescents
have a higher risk for type 2 diabetes. Subclinical inflammation and
reduced glucagon-like peptide 1 (GLP-1) concentration are linked to the
pathogenesis of the disease. We determined the relationship between insulin
resistance, beta-cell activity, and subclinical inflammation with GLP-1
concentrations and whether racial disparities in GLP-1 response were
present in 49 obese adolescents (14 +/- 3 years; 76% African American; 71%
female). Research design and methods: Subjects underwent physical examination and
an oral glucose tolerance test. We measured levels of high-sensitivity CRP
(CRP(hs)), fibrinogen, glucose, GLP-1(total), GLP-1(active), and insulin.
Insulin and glucose area under the curve (AUC), insulinogenic index
(DeltaI30/DeltaG30), and composite insulin sensitivity index (CISI) were
computed. Subjects were categorized by race and as inflammation positive
(INF+) if CRP(hs) or fibrinogen were elevated. Results: No racial differences were seen in mean or relative BMI.
Thirty-five percent of subjects had altered fasting or 2-h glucose levels
(African American vs. Caucasian, NS), and 75% were INF+ (African American
vs. Caucasian, P = 0.046). Glucose and insulin, CISI, and DeltaI30/DeltaG30
values were similar; African Americans had lower GLP-1(total) AUC (P =
0.01), GLP-1(active) at 15 min (P = 0.03), and GLP-1(active) AUC (P = 0.06)
and higher fibrinogen (P = 0.01) and CRP(hs) (NS) compared with Caucasians. Conclusions: African Americans exhibited lower GLP-1 concentrations and
increased inflammatory response. Both mechanisms may act synergistically to
enhance the predisposition of obese African Americans to type 2 diabetes.
Our findings might be relevant to effective deployment of emerging
GLP-1-based treatments across ethnicities.


Interested in this research and working with us? Please contact us here.